HIQA advises Minister for Health to introduce a PrEP programme to prevent HIV

share on facebook tweet this

HIQA advises Minister for Health to introduce a PrEP programme to prevent HIV

Date of publication: Friday, 14 June, 2019

The Health Information and Quality Authority (HIQA) has published a health technology assessment recommending the introduction of a pre-exposure prophylaxis (PrEP) programme for populations at substantial risk of sexual acquisition of HIV. HIQA has advised the Minister for Health that the HTA found that the successful implementation of a national PrEP programme in Ireland would be safe, effective and cost-saving.
 
Following a public consultation, the Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV was approved by the Board of HIQA this week and has been submitted to the Minister for Health for his consideration.
 
HIQA's Director of Health Technology Assessment and Deputy Chief Executive, Dr Máirín Ryan, said: "HIV infection remains a significant public health concern. There were 492 diagnoses of HIV notified in Ireland in 2017. Just over half of all notifications were in men who have sex with men.
 
" PrEP is the most recent development in the field of HIV prevention, involving the pre-emptive use of oral antiretroviral therapy in HIV negative people to prevent infection. PrEP consists of a fixed dose combination of oral tenofovir/emtricitabine and has been licensed for use in Ireland since 2016. A 'PrEP programme' provides PrEP as part of a holistic service that includes frequent monitoring for adherence and side effects, testing for HIV and other STIs, and counselling and advice on safer sex practices.
 
Dr Ryan continued "From reviewing the evidence, HIQA has found that PrEP is safe and highly effective at preventing HIV in people at substantial risk. Additionally, implementing a PrEP programme would be considered cost saving compared with standard care. The effectiveness of PrEP is strongly linked with taking the medication correctly, and PrEP must not be taken by individuals with an unrecognised HIV infection as drug resistance mutations may develop. This means that it is important that people taking part in a PrEP programme should receive advice on taking the medication appropriately and undergo frequent HIV testing."
 
Dr Ryan concluded "The primary barriers to introducing a PrEP programme in public STI clinics in Ireland relate to staffing and infrastructural issues. A significant investment in STI services is required for a national PrEP programme to ensure a safe, sustainable and equitable service."
 
The HTA is available from the link below and includes an executive summary and a plain English summary.